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A B S T R A C T
Background
Osteoarthritis is themost common formof joint disease and the leading cause of pain and disability in the elderly. S-Adenosylmethionine
may be a viable treatment option but the evidence about its effectiveness and safety is equivocal.
Objectives
We set out to compare S-Adenosylmethionine (SAMe) with placebo or no specific intervention in terms of effects on pain and function
and safety outcomes in patients with knee or hip osteoarthritis.
Search strategy
We searched CENTRAL, MEDLINE, EMBASE, CINAHL and PEDro up to 5 August 2008, checked conference proceedings and
reference lists, and contacted authors.
Selection criteria
Randomised or quasi-randomised controlled trials that compared SAMe at any dosage and in any formulation with placebo or no
intervention in patients with osteoarthritis of the knee or hip.
Data collection and analysis
Two independent authors extracted data using standardised forms. We contacted investigators to obtain missing outcome information.
We calculated standardised mean differences (SMDs) for pain and function, and relative risks for safety outcomes. We combined trials
using inverse-variance random-effects meta-analysis.
Main results
Four trials including 656 patients were included in the systematic review, all compared SAMe with placebo. The methodological quality
and the quality of reporting were poor. For pain, the analysis indicated a small SMD of -0.17 (95% CI -0.34 to 0.01), corresponding
to a difference in pain scores between SAMe and placebo of 0.4 cm on a 10 cm VAS, with no between trial heterogeneity (I2 = 0).
For function, the analysis suggested a SMD of 0.02 (95% CI -0.68 to 0.71) with a moderate degree of between-trial heterogeneity (I2
= 54%). The meta-analyses of the number of patients experiencing any adverse event, and withdrawals or drop-outs due to adverse
events, resulted in relative risks of 1.27 (95% CI 0.94 to 1.71) and 0.94 (95% CI 0.48 to 1.86), respectively, but confidence intervals
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were wide and tests for overall effect were not significant. No trial provided information concerning the occurrence of serious adverse
events.
Authors’ conclusions
The current systematic review is inconclusive, hampered by the inclusion of mainly small trials of questionable quality. The effects of
SAMe on both pain and function may be potentially clinically relevant and, although effects are expected to be small, deserve further
clinical evaluation in adequately sized randomised, parallel-group trials in patients with knee or hip osteoarthritis. Meanwhile, routine
use of SAMe should not be advised.
P L A I N L A N G U A G E S U M M A R Y
S-Adenosylmethionine (SAMe) for osteoarthritis
This summary of a Cochrane review presents what we know from research about the effect of S-Adenosylmethionine on osteoarthritis.
The review shows that in people with osteoarthritis:
- We are uncertain whether S-Adenosylmethionine affects pain or your ability to use your knee because of the low to moderate quality
of the evidence.
- S-Adenosylmethionine may not have any side effects. We often do not have precise information about side effects and complications.
This is particularly true for rare but serious side effects.
What is osteoarthritis and what is S-Adenosylmethionine (SAMe)?
Osteoarthritis (OA) is a disease of the joints, such as your knee or hip. When the joint loses cartilage, the bone grows to try to repair
the damage. Instead of making things better, however, the bone grows abnormally and makes things worse. For example, the bone can
become misshapen and make the joint painful and unstable. This can affect your physical function or ability to use your knee.
S-Adenosylmethionine is popular dietary supplement available over the counter in drug stores or health food stores. It is also a naturally
occurring chemical that is produced in the body. SAMe is not found in foods, so it must be taken as a supplement.
Best estimate of what happens to people with osteoarthritis who take S-Adenosylmethionine (SAMe)
Pain
- People with S-Adenosylmethionine and people with placebo are equally likely to respond to treatment (difference of 0%). This could
be the result of chance.
- People who took S-Adenosylmethionine had an improvement in their pain of about 2 on a scale from 0 (no pain) to 10 (extreme
pain) after using it up to 3 months.
- People who took a placebo had an improvement in their pain of also about 2 on a scale from 0 (no pain) to 10 (extreme pain) after
using it up to 3 months.
Physical Function
- People with S-Adenosylmethionine and people with placebo are equally likely to respond to treatment (difference of 0%). This could
be the result of chance.
- People who took S-Adenosylmethionine had an improvement in their physical function of about 1 on a scale of 0 (no disability) to
10 (extreme disability) after using it up to 3 months.
- People who took a placebo had an improvement in their physical function of also about 1 on a scale of 0 (no disability) to 10 (extreme
disability) after using it up to 3 months.
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Side effects
- 4 more people experienced side effects with S-Adenosylmethionine than with placebo (difference of 4%). This could be the result of
chance.
- 19 people out of 100 who used S-Adenosylmethionine experienced side effects (19%).
- 15 people out of 100 who used a placebo experienced side effects (15%).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [ Explanation]
S-Adenosylmethionine compared with placebo or no intervention for osteoarthritis of the knee or hip
Patient or population: Patients with osteoarthritis of the knee or hip
Settings: Outpatient clinic of either rheumatologic, orthopedic or veteran’s hospital departments
Intervention: S-Adenosylmethionine
Comparison: Placebo or no intervention
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo or no intervention S-Adenosylmethionine
Pain
Various validated pain
scales
Follow-up: 3 to 12 weeks
-1.8 cm change
on 10 cm VAS1
29% improvement
-2.2 cm change
(1 -0.4 cm, -0.9 to 0.0
cm)2
37% improvement
(1 8%, 0% to 15%)3
SMD -0.17 (-0.35 to 0.01) 533
(2 studies)
+++O
moderate4
Little evidence of beneficial
effect (NNT: not statistically
significant)
Function
Various validated function
scales
Follow-up: 3 to 12 weeks
-1.2 units on WOMAC
(range 0 to 10)1
21% improvement
-1.2 units on WOMAC
(1 0.0, -1.4 to +1.5)5
21% improvement
(1 0%, -26% to +26%)6
SMD 0.02 (-0.68 to 0.71) 542
(3 studies)
++OO
low7
Little evidence of beneficial
effect (NNT: not statistically
significant)
Number of patients ex-
periencing any adverse
event
Follow-up: 3 to 12 weeks
150 per 1000 patient-
years1
191 per 1000
(141 to 257)
RR 1.27
(0.94 to 1.71)
632
(4 trials)
+++O
moderate8
Little evidence of harmful
effect (NNH: not statisti-
cally significant)
Number of patients who
withdrew because of ad-
verse events
Follow-up: 3 to 12 weeks
17 per 1000 patient-years1 16 per 1000
(8 to 32)
RR 0.94
(0.48 to 1.86)
656
(4 trials)
+++O
moderate9
Little evidence of harmful
effect (NNH: not statisti-
cally significant)
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Number of patients expe-
riencing any serious ad-
verse event
Median follow-up: x weeks
See comment See comment Not estimable 0 (0 trials) See comment 0 trials provided data for
this outcome
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in
the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; GRADE: GRADE Working Group grades of evidence (see explanations); SMD: standardised mean difference; NNT: number needed to treat; NNH: number needed to harm
GRADE Working Group grades of evidence
High quality (++++): Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality (+++O): Further research is likely to have an important impact on our confidence in the estimate of effect and may
change the estimate.
Low quality (++OO): Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely
to change the estimate.
Very low quality (+OOO): We are very uncertain about the estimate.
1 Median reduction as observed across control groups in large osteoarthritis trials (Nüesch 2009).
2 Standardised mean differences (SMDs) were back-transformed onto a 10 cm visual analogue scale (VAS) on the basis of a typical
pooled SD of 2.5 cm in trials that assessed pain using a VAS, and expressed as change based on an assumed standardised reduction of
0.72 standard deviation units in the control group.
3 The median observed pain score at baseline across control groups in large osteoarthritis trials was 6.1 cm on a 10 cm VAS (Nüesch
2009).
4 Downgraded (1 level) because analyses was not according to intention-to-treat principle, 2 out of 4 trials reported this outcome,
potentially leading to selective outcome reporting bias, 1 out of 2 trials used adequate, 1 used unclear concealment of allocation methods,
possible indirectness of evidence (indirect population) in 1 out of 2 studies.
5 Standardised mean differences (SMDs) were back-transformed onto a 0 to 10 standardised WOMAC function score on the basis of
a typical pooled SD of 2.1 in trials that assessed function on WOMAC function scale and expressed as change based on an assumed
standardised reduction of 0.58 standard deviation units in the control group.
6 The median observed standardised WOMAC function score at baseline across control groups in large osteoarthritis trials was 5.6 units
(Nüesch 2009).
7 Downgraded (2 levels) because: analyses was not according to intention-to-treat principle, presence of moderate between-trial
heterogeneity, possible indirectness of evidence (indirect population) in 2 out of 3 studies, the confidence interval is wide and crossed
no difference, 1 out of 3 trials used adequate, 2 used unclear concealment of
allocation methods.
8 Downgraded (1 level) because the confidence interval crosses no difference, in 1 out of 4 trials analyses was not according to intention-
to-treat principle.
9 Downgraded (1 level) because the confidence interval is wide and crossed no difference.5
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B A C K G R O U N D
Osteoarthritis is a degenerative disease characterised by focal areas
of loss of articular cartilage in synovial joints, subchondral bone
changes, osteophyte formation at the joint margins, thickening of
the joint capsule andmild synovitis (Altman 1996). Symptoms in-
clude pain, stiffness and decreased range of motion, limiting daily
activities and reducing quality of life. To manage the symptoms
of osteoarthritis, patients and healthcare providers often resort
to multiple approaches, including lifestyle modifications, medica-
tions, exercise or surgery. Non-steroidal anti-inflammatory drugs
(NSAIDs) are themainstay ofmanagement for osteoarthritic pain,
but may cause serious gastrointestinal and cardiovascular adverse
events.
Beneficial effects of the dietary supplement S-Adenosylmethionine
(SAMe) have been intensively advertised. Within a few years the
supplement has become popular, surrounded by countless claims
concerning its effectiveness with fewer side effects. SAMe is pro-
posed for use as an antidepressant, a medication for cholestasis
and liver disorders, a treatment for migraines, and therapy for fi-
bromyalgia and osteoarthritis. The rationale for a general thera-
peutic applicationof SAMe stems from the hypothesis that subnor-
mal biologically active levels of this substance will be normalised
by a parenteral or peroral administration in a variety of organ sys-
tems. SAMe is deemed to induce beneficial changes in the indi-
vidual, whose problems - at least in part - are related to a rela-
tive deficiency of the compound (Fetrow 2001). In osteoarthritis,
the exact mechanism remains controversial. It is suggested that
there is a mismatch between generative and degenerative forces
that govern cartilage formation, partly because of a malfunction
in proteoglycan synthesis. One in vitro study of SAMe (Harmand
1987) suggested that it may favourably affect the synthesis of pro-
teoglycans. Additional mechanisms of SAMe in reducing pain in
osteoarthritis include a reduction of inflammation and direct anal-
gesic effects at central or peripheral levels, potentially mediated
through a cyclo-oxygenase inhibition.
Initial studies with SAMe used the parenteral route exclusively
due to the instability of the oral form. As additional work allowed
the development of a stable oral form of SAMe, further studies
tested the effectiveness of the oral form in the management of
several medical conditions including osteoarthritis. Four reviews
on SAMe for osteoarthritis have been published (di Padova 1987;
Hardy 2002; Soeken 2002; Witte 2002). Three are systematic re-
views including a meta-analysis (Hardy 2002; Soeken 2002;Witte
2002) and the fourth is a narrative, general overview of articles (di
Padova 1987). Similar conclusions were drawn in these reviews:
that the results of the available studies were heterogeneous and did
not allow firm claims to be made about the effectiveness of SAMe
in the management of osteoarthritis.
O B J E C T I V E S
We set out to compare S-Adenosylmethionine (SAMe) with
placebo or no specific intervention in terms of effects on pain
and function and safety outcomes in patients with knee or hip
osteoarthritis and to explore whether potential variation between
trials could be explained by biases affecting individual trials or by
publication bias.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised controlled trials were eligible.
Trials using an unpredictable allocation sequence were considered
as randomised.
Types of participants
Trials including at least 75% of patients with clinically and/or ra-
diologically confirmed osteoarthritis of the knee or hip. We ex-
cluded trials which evaluated SAMe after knee or hip surgery.
Types of interventions
We considered trials involving administration of S-Adenosylme-
thionine at any dosage and in any formulation. Eligible control
interventions were placebo or a non-intervention control (usual
care).
Types of outcome measures
Main outcomes
Main outcomes were pain and function, as currently recom-
mended for osteoarthritis trials (Altman 1996; Pham 2004). If
data on more than one pain scale were provided for a trial, we
referred to a previously described hierarchy of pain-related out-
comes (Jüni 2006; Reichenbach 2007) and extracted data on the
pain scale that is highest on this list:
1. Global pain
2. Pain on walking
3. WOMAC osteoarthritis index pain subscore
4. Composite pain scores other than WOMAC
5. Pain on activities other than walking
6. Rest pain or pain during the night
7. WOMAC global algofunctional score
8. Lequesne osteoarthritis index global score
9. Other algofunctional scale
10. Patient’s global assessment
11. Physician’s global assessment
If data on more than one function scale were provided for a trial,
we extracted data according to the hierarchy presented below.
1. Global disability score
2. Walking disability
3. WOMAC disability subscore
6S-Adenosylmethionine for osteoarthritis of the knee or hip (Review)
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4. Composite disability scores other than WOMAC
5. Disability other than walking
6. WOMAC global scale
7. Lequesne osteoarthritis index global score
8. Other algofunctional scale
9. Patient’s global assessment
10. Physician’s global assessment
If pain or function outcomes were reported at several time points,
we extracted the measure at the end of the treatment period.
Secondary outcomes
Secondary outcomes included the number of patients experienc-
ing any adverse event, patients who were withdrawn or dropped
out because of adverse events, and patients experiencing any seri-
ous adverse events. We extracted end of trial data for these out-
comes. We defined serious adverse events as events resulting in
in-patient hospitalisation, prolongation of hospitalisation, persis-
tent or significant disability, congenital abnormality/birth defect
of offspring, life-threatening events or death.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (The Cochrane Library 2008, issue 3), MED-
LINE (1966 to 5 August 2008) and EMBASE (1975 to 5 Au-
gust 2008) through the Ovid platform ( www.ovid.com), and
CINAHL (1937 to 5 August 2008) through EBSCOhost, using
truncated variations of preparationnames, includingbrand names,
combinedwith truncated variations of terms related to osteoarthri-
tis, as well as MESH headings. We applied a validated method-
ological filter for controlled clinical trials (Dickersin 1994). The
specific search algorithms are displayed in Appendix 1 for MED-
LINE, EMBASE and CINAHL, and in Appendix 2 for CEN-
TRAL.
Searching other resources
We manually searched conference proceedings. We used Science
Citation Index to retrieve reports citing the relevant articles. We
screened reference lists of all obtained articles, including related
reviews.We contacted content experts and trialists and asked them
for relevant references. Finally, we searched several clinical trial
registries ( www.clinicaltrials.gov, www.controlled- trials.com,
www.actr.org.au, www.umin.ac.jp/ ctr) to identify ongoing trials.
The last update of the manual search was on 28 July 2008.
Data collection and analysis
Selection of studies
Two review authors (AR and EN) independently evaluated all
yielded titles and abstracts for eligibility (see Figure 1).We resolved
disagreements by discussion. We applied no language restrictions.
In case of multiple reports relating to the same trial, we considered
all reports.
Figure 1. Study flow chart
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Data extraction and management
Two review authors (AR and SR or EN) independently extracted
trial information using a standardised, piloted extraction form
accompanied by a codebook. We resolved disagreements by dis-
cussion. We extracted the generic and the trade name of SAMe,
the type of control used, dosage, frequency and duration of treat-
ment, patient characteristics (average age, gender, mean duration
of symptoms, type of joints affected), type of pain- and function-
related outcome extracted, trial design, trial size, duration of fol-
low up, type and source of financial support and publication status
from trial reports. When necessary, we approximated means and
measures of dispersion from figures in the reports. For cross-over
trials, we extracted data from the first period only because of possi-
ble carry-over effects. Whenever possible, we used results from an
intention-to-treat analysis. If effect sizes could not be calculated,
we contacted the authors for additional data.
Assessment of risk of bias in included studies
Two review authors (AR and SR or EN) independently assessed
randomisation, blinding and adequacy of analyses (Jüni 2001).We
resolved disagreements by consensus.We assessed two components
of randomisation: generation of allocation sequences and conceal-
ment of allocation. The generation was considered adequate if it
resulted in unpredictable allocation sequences; mechanisms con-
sidered adequate include random-number tables, computer-gen-
erated random numbers, minimisation, coin tossing, shuffling of
cards and drawing of lots. Trials using an unpredictable allocation
sequence were considered randomised; trials using potentially pre-
dictable allocation mechanisms, such as alternation or the alloca-
tion of patients according to date of birth, were considered quasi-
randomised. We considered allocation concealment adequate if
the investigators responsible for patient selection were unable to
suspect before allocation which treatment was next; methods con-
sidered adequate include central randomisation, pharmacy con-
trolled randomisation using identical pre-numbered containers,
and sequentially numbered, sealed, opaque envelopes. We consid-
ered blinding of patients adequate if the preparations were explic-
itly described as indistinguishable or if a double-dummy technique
was used. We considered analyses adequate if all randomised pa-
tients were included in the analysis according to the intention-to-
treat principle. Finally, we used GRADE to describe the quality of
the overall body of evidence (Guyatt 2008;Higgins 2008), defined
as the extent of confidence in the estimated treatment benefits and
harms.
Data synthesis
We summarised continuous outcomes using standardised mean
differences (SMD), with the differences in mean values at the end
of follow up across treatment groups divided by the pooled stan-
dard deviation. If differences in mean values at the end of the fol-
low up were unavailable, we used differences in mean changes. If
some of the required data were unavailable, we used approxima-
tions as previously described (Reichenbach 2007). A SMD of -
0.20 standard deviation units can be considered a small difference
between experimental and control group, a SMD of -0.50 a mod-
erate difference, and -0.80 a large difference (Cohen 1988; Jüni
2006). SMDs can also be interpreted in terms of the percent of
overlap of the experimental group’s scoreswith scores of the control
group. A SMD of -0.20 indicates an overlap in the distributions
of pain or function scores in about 85% of cases, a SMD of -0.50
in approximately 67%, and a SMD of -0.80 in about 53% of cases
(Cohen 1988; Jüni 2006). On the basis of a median pooled SD of
2.5 cm found in large-scale osteoarthritis trials that assessed pain
using a 10 cm visual analogue scale (VAS) (Nüesch 2009), SMDs
of -0.20, -0.50 and -0.80 correspond to approximate differences
in pain scores between experimental and control groups of 0.5,
1.25 and 2.0 cm on a 10 cm VAS. SMDs for function were back
transformed to a standardised WOMAC disability score (Bellamy
1995) ranging from 0 to 10, on the basis of a median pooled SD
of 2.1 units observed in large-scale osteoarthritis trials (Nüesch
2009). We expressed binary outcomes as risk ratios (RR).
We used standard inverse-variance random-effects meta-analysis
to combine the trials (DerSimonian 1986). We quantified hetero-
geneity between trials using the I2 statistic (Higgins 2003), which
describes the percentage of variation across trials that is attributable
to heterogeneity rather than to chance and the corresponding χ2
test. I2 values of 25%, 50% and 75% may be interpreted as low,
moderate and high between-trial heterogeneity, although the in-
terpretation of I2 depends on the size and number of trials included
(Rucker 2008). Then, we converted SMDs of pain intensity and
function to odds ratios (Chinn 2000) to derive numbers needed to
treat (NNT) to cause one additional treatment response on pain
or function as compared with control, and numbers needed to
harm (NNH) to cause one additional adverse outcome. We de-
fined treatment response as a 50% improvement in scores (Clegg
2006), which corresponds to an average decrease of 1.2 standard
deviation units (Nüesch 2009). With a median standardised pain
intensity at baseline of 2.4 standard deviation units and a me-
dian standardised decrease in pain scores of 0.72 standard devi-
ation units observed in large osteoarthritis trials (Nüesch 2009),
we calculated that a median of 31% of patients in the control
group would achieve an improvement of pain scores of 50% or
more. This percentage was used as the control group response rate
to calculate NNTs for treatment response on pain. Based on the
median standardised WOMAC function score at baseline of 2.7
standard deviation units and the median standardised decrease in
function scores of 0.58 standard deviation units (Nüesch 2009),
26% of patients in the control group would achieve a reduction
in function of 50% or more. Again, this percentage was used as
the control group response rate to calculate NNTs for treatment
response on function. We used median risks of 150 patients with
adverse events per 1000 patient-years, four patients with serious
adverse events per 1000 patient-years and 17 drop-outs due to
adverse events per 1000 patient-years, observed in placebo groups
in large osteoarthritis trials (Nüesch 2009), to calculate NNHs for
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safety outcomes.
All P values are two-sided. We performed the data analysis in
RevMan version 5 (RevMan 2008) and STATA version 10.1 (Stat-
aCorp, College Station, Texas).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
We identified 231 references to articles and considered 37 to be
potentially eligible (Figure 1). Five reports describing four com-
pleted trials in 656 patients met our inclusion criteria. Contacting
experts and checking conference readings and trial registers did
not result in the identification of additional RCTs.
Three small sized trials used a two-arm parallel-group design
to compare SAMe with placebo (Bradley 1994; König 1990;
Montrone 1985). A large sized multicentre study by Caruso and
Pietrogrande used a three-arm parallel-group design to compare
SAMe with naproxen and placebo (Caruso 1987). The trial arm
involving naproxenwas excluded from this review. Duration of the
studies ranged from three (Montrone 1985) to 12 weeks (König
1990); follow up was at the end of trial in all studies.
In all studies patients had a clinical severity requiring simple non-
surgical treatments (Jüni 2006), three trials included patient with
functional classes II and Ill and definite radiological signs of os-
teoarthritis, but one trial included patients without typical ra-
diographic signs (König 1990). In two trials, only patients with
osteoarthritis of the knee were included (Bradley 1994; König
1990), while the trial by Montrone 1985 included both: 51 pa-
tients (67%) with knee osteoarthritis and 25 (33%) patients with
hip osteoarthritis. Caruso 1987 included knee (55%), hip (24%),
hand (7%) and spine osteoarthritis (14%). Despite the description
of an adequately concealed randomisation with stratification for
study centre, the patient population in the two centres in Bradley
1994 differed. At one site, the majority of the patients were fe-
male (85%) with an average age of 58 years and an average disease
duration of 10.9 years. At the other site, only 21% of the patients
were female with a average age of 63 years and an average disease
duration of 12.4 years.
SAMe and placebo were applied orally in all studies. However, one
study started with intravenous SAMe for the first five days before
switching to an oral formulation of the interventions (Bradley
1994). Oral doses of SAMe used were 200 mg three times per
day (Bradley 1994), 400 mg three times per day (König 1990;
Montrone 1985) or 400 mg six times per day (Caruso 1987).
One trial allowed the use of analgesics (Bradley 1994), another
explicitly did not (Caruso 1987), and two trials did not report on
analgesic co-interventions (König 1990; Montrone 1985).
We excluded 12 studies because SAMe was compared to ac-
tive control interventions: ibuprofen was used in six studies (
Capretto1985; Ceccato 1980; Cucinotta 1980; Glorioso 1985;
Marcolongo 1985; Muller-Fassbender 1987), and naproxen, as-
pirin, indomethacin, piroxicam, celecoxib, sulindac and in-
domethacin were used in one study each as comparators (Caroli
1980; Domljan 1989; Maccagno 1987; Najm 2004; Pellegrini
1980; Vetter 1987). The ’Characteristics of excluded studies’ table
presents the main reasons for exclusion of other studies.
Risk of bias in included studies
One study reported adequate generation of the randomisation se-
quence and adequate allocation concealment using coded phar-
macy (Bradley 1994, Figure 2). The study of Caruso 1987 re-
ported the use of block randomisation but did not report how
blocks were generated, nor the method used for concealment of
allocation. The other two studies were unclear about the methods
used to randomise patients (König 1990; Montrone 1985).
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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All trials were described as double-blind. Three trials reported the
use of indistinguishable interventions to blind patients (Bradley
1994; Caruso 1987; Montrone 1985), but only Montrone 1985
explicitly described that patients, physicians and assessors were
blinded. In Bradley 1994 and Caruso 1987 only adequate blind-
ing of patients could be assumed. The remaining study did not
describe blinding of patients or physicians, nor did it describe the
use of an indistinguishable placebo control (König 1990).
None of the trials was considered to have performed an intention-
to-treat analysis for any of the primary outcomes. All trials ex-
plicitly reported exclusion of randomised patients. Percentages of
exclusions ranged from 5.2% to 18% in experimental groups and
from 0% to 8% in control groups. One trial did not report the
overall number of patients randomly allocated and the percentage
of exclusions could not be determined (Bradley 1994).
Three trials failed to report the specification of a primary out-
come and failed to present power calculations. The fourth trial by
Bradley 1994 reported three separate pain scales as primary out-
comes. Although this trial also reported a protocol based sample
size calculation, it was unclear onwhich of the three pain outcomes
the difference used in the calculation was based (Bradley 1994).
Two trials were funded by amanufacturer of SAMe (Bradley 1994;
Caruso 1987), whereas the source of funding was unclear in the
the other two trials.
Effects of interventions
See: Summary of findings for the main comparison
Pain intensity
Two trials with two comparisons (533 patients) contributed to the
meta-analysis of pain outcomes (Figure 3). The analysis suggested
a small SMD of -0.17 (95% CI -0.35 to 0.01) for pain which cor-
responds to a difference in pain scores of 0.4 cm on a 10 cm VAS,
a difference in improvement from baseline of 8% (95% CI 0%
to +15%) between SAMe and control (see ’Summary of findings
for the main comparison’). An I2 of 0% indicated the absence of
between-trial heterogeneity (P for heterogeneity = 0.92), which
was confirmed by visual inspection.
Figure 3. Forest plot of 2 trials comparing the effects of S-Adenosylmethionine and control (placebo or no
intervention) on knee or hip pain. Values on x-axis denote standardised mean differences.
Function
Three trials (542 patients) contributed to the meta-analyses of
function (Figure 4). The analysis suggested a negligible SMD of
0.02 (95% CI -0.68 to 0.71, see ’Summary of findings for the
main comparison’). An I2 of 54% indicated a moderate degree
of between-trial heterogeneity (P for heterogeneity = 0.11). On
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visual inspection, the variation could be explained by the trial by
König 1990 that estimated an effect size favouring control. Ex-
cluding König 1990 in a sensitivity analysis, we found a SMD of -
0.15 (95% CI -0.33 to 0.03), which corresponds to a difference in
function scores of 0.3 units on a standardised WOMAC disability
scale ranging from 0 to 10 and a difference in improvement of 6%
(95% CI 0% to +13%) between SAMe and control, and a reduc-
tion of between-trial heterogeneity to 0% (P for heterogeneity =
0.11).
Figure 4. Forest plot of 3 trials comparing the effects of S-Adenosylmethionine and control (placebo or no
intervention) on function. Values on x-axis denote standardised mean differences.
Safety
All trials (623 patients) contributed to the meta-analysis of pa-
tients experiencing any adverse event (Figure 5). The analysis sug-
gested a RR of 1.27 (95% CI 0.94 to 1.71). An I2 of 0% suggested
an absence of between-trial heterogeneity (P for heterogeneity =
0.39). All trials (656 patients) contributed to the meta-analysis
of patients withdrawn or dropped out because of adverse events (
Figure 6). The analysis yielded a RR of 0.94 but confidence inter-
vals were wide (95%CI 0.48 to 1.86). An I2 of 0% again suggested
an absence of between-trial heterogeneity (P for heterogeneity =
0.76). None of the trials contributed to the meta-analysis of pa-
tients experiencing any serious adverse event.
Figure 5. Forest plot of 4 trials comparing patients experiencing any adverse event between S-
adenosylmethionine and control (placebo or no intervention). Values on x-axis denote risks ratios.
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Figure 6. Forest plot of 4 trials comparing patients who withdrew because of adverse events between S-
adenosylmethionine and control (placebo or no intervention). Values on x-axis denote risks ratios.
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D I S C U S S I O N
Summary of main results
Our systematic review of trials comparing S-Adenosylmethionine
(SAMe) with a placebo control revealed a lack of adequately sized,
methodologically sound and appropriately reported trials and a
moderate degree of heterogeneity between trials reporting func-
tion outcomes, which made the interpretation of results difficult.
Overall effect sizes for pain and function seemed small. We found
little evidence to suggest that SAMe is unsafe, but 95% confidence
intervals (CI) were wide and therefore inconclusive.
Quality of the evidence
The methodological quality and the quality of reporting in the
trials was poor. All but one had small sample sizes. Insufficient in-
formation about the generation of allocation sequences and con-
cealment of allocation was noted in three out of four randomised
controlled trials. None of the trials performed analyses according
to the intention-to-treat principle. All trials failed to describe seri-
ous adverse events, which is concerning. Due to the low number
of trials identified, we were unable to explore the effects of dosing,
route of administration, methodological quality or type of fund-
ing.
Potential biases in the review process
Our review is based on a broad literature search, and it seems
unlikely that we missed relevant trials (Egger 2003). Trial selec-
tion and data extraction, including quality assessment, were done
independently by two authors to minimise bias and transcrip-
tion errors (Egger 2001). Components used for quality assessment
are validated and reported to be associated with bias (Jüni 2001;
Wood 2008). As with any systematic review, our study is limited
by the quality of included trials. As indicated above, trials generally
suffered from poor methodological quality, inadequate reporting
and small sample size. One trial showed an unrealistically large
unfavourable standardised mean difference (SMD) for function,
which can best be explained by chance, as the study included only
nine patients (König 1990). Including this trial in the meta-anal-
ysis may result in a slight underestimation of the benefit of SAMe
on function. We included a trial described as a double-blind study
in a published letter, although the report did not specifically men-
tion the use of randomisation. Exclusion of this study would not
have altered any of our conclusions.
Agreements and disagreements with other
studies or reviews
We are aware of two systematic reviews that compared the efficacy
of SAMe with placebo on pain and function (Soeken 2002; Witte
2002). In line with our review, the authors did not find a statisti-
cal significant improvement in pain (SMD -0.22, 95% CI -0.69
to 0.25 in Soeken 2002; -0.38, 95% CI -0.89 to 0.12 in Witte
2002). In contrast to our conclusions, Soeken 2002 concluded
that SAMe, when compared to placebo, was effective in reducing
functional limitations (SMD-0.31, 95%confidence interval -0.52
to -0.10). They further concluded that the tolerability of SAMe
was similar to that of placebo and greater than that of NSAIDs.
The difference in conclusions regarding improvement of function
can be explained by differences in outcome definitions and inclu-
sion criteria. Soeken 2002 choose restriction in joint movement
as an outcome, whereas we choose a different approach, using a
hierarchy developed to minimise the impact of selective reporting
of outcomes and to allow for a synthesis of evidence across differ-
ent studies using divergent definitions of function. In the review
of Soeken 2002, only Caruso 1987 contributed to the analysis of
function, whereas we could include two additional trials (Bradley
1994 and König 1990). The odds ratio of 1.37 (95% CI 0.81 to
2.32) for patients experiencing adverse events in Soeken 2002 was
comparable to our pooled relative ratio of 1.27 (95% CI 0.94 to
1.71).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Routine use of S-Adenosylmethionine (SAMe) should not be
recommended until further trials of adequate sample size and
methodology suggest a clinically relevant effectiveness.
Implications for research
To allow unequivocal conclusions to be drawn regarding the ef-
fects of SAMe on both pain relief and function, and on safety,
additional adequately powered, double-blind, placebo controlled
trials should be performed. Special attention needs to be given to
the use of adequate randomisation with appropriate concealment
of allocation and an analysis according to the intention-to-treat
principle. Although a daily intake of 1200 mg (orally) may be a
reasonably effective dose with an acceptable safety profile, further
clarification of the optimal dose is necessary.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bradley 1994
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 4 weeks
Randomisation stratified according to centre
Multicentre trial with 2 centres
Power calculation: reported and protocol based for 3 pain scales
Funding by non-profit organisation: no information provided
Participants 48 patients were randomised in study centre A*, 33 in study centre B
81 patients with osteoarthritis were reported at baseline
Affected joints: 81 knees
Number of females: 41 of 48 (85%) in centre A, 7 of 33 (21%) in centre B
Average age: 58 years in centre A, 63 years in centre B
Average disease duration: 10.9 years in centre A, 12.4 years in centre B
Radiographic severity of OA: (% grade 2/% grade 3) in site A: 62.5%/37.5% in SAMe,
54%/46% in placebo. In site B: 59%/41% in SAMe, 69%/31% in placebo
Interventions Experimental intervention: S-Adenosylmethionine, on 5 consecutive days intravenous
400 mg once daily, then oral 200 mg 3 times daily
Control intervention: placebo, on 5 consecutive days intravenous once daily, then oral
3 times daily
Treatment duration: 4 weeks
Analgesics other than study drugs allowed, intake assessed and found to be lower in
SAMe group compared to placebo at site A, and higher in SAMe compared to placebo
at site B.
Outcomes Extracted pain outcome: pain on walking after 4 weeks, described as “walking pain”
Extracted function outcome: walking disability after 4 weeks, described as “walking
distance before having to stop because of knee pain”
Primary outcome: > 2 reported; for HAQ pain, rest pain and walking pain
Notes *In the original report the investigators presented results separately for site A and B,
because the randomisation, although concealed, resulted in marked baseline differences
between patients at the 2 sites with respect to demographic and disease related charac-
teristics
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Use of random-number table
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Bradley 1994 (Continued)
Allocation concealment? Yes Use of coded pharmacy
Blinding of patients? Yes The trial was described as a double-blind study randomising
patients to indistinguishable interventions
Blinding of physicians? Unclear No information provided
Blinding of outcome assessors? Unclear No information provided
Interventions reported as indistinguish-
able?
Yes Quote: “Placebo Injectate and placebo tablets were employed
that contained the same stabilizers and inert ingredients as the
active agent and were packaged identically.”
Double-dummy technique used? No -
Intention-to-treat analysis performed?
Pain
No Center A: no information provided. Center B: 13 out of 17
(76%) in SAMe group, 14 out of 16 (87%) in placebo group
analysed.
Intention-to-treat analysis performed?
Function
No See above
Funding by commercial organisation
avoided?
No Supported by a grant from Asta Medica
Caruso 1987
Methods Randomised controlled trial
3-arm parallel group design*
Trial duration: 30 days
Randomisation stratified according to centre and type of joint
Multicentre trial with 33 centres
Power calculation: not reported
Funding by non-profit organisation: no information provided
Participants 489 SAMe and placebo patients were randomised
489 SAMe and placebo patients with osteoarthritis were reported at baseline
Affected joints: 272 knees, 115 hips, 69 spines, 33 hands
Number of females: 368 of 489 (75%)
Average age: 59 years
Average disease duration: 6.1 years
Radiographic severity of OA: functional classes II and Ill according to the classification
of the American Rheumatism Association (ARA)
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Caruso 1987 (Continued)
Interventions Experimental intervention: S-Adenosylmethionine, oral 200mg 6 times daily
Control intervention: placebo, 6 times daily
Treatment duration: 4.2 weeks (30 days)
Analgesics other than study drugs not allowed
Outcomes Extracted pain outcome: global pain after 4 weeks, described as “diurnal pain”
Extracted function outcome: walking disability after 4 weeks, described as “degree of
difficulty while walking on a plane”
No primary outcome reported
Notes *The trial armwith intervention naproxenwas excluded from this review. Randomisation
blocks numbered from 19 to 24 could only be used for enrolment of patients with spine
and hand osteoarthritis.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Block randomisation was used to allocate patients, but it re-
mained unclear how blocks were generated. Quotes: “Twenty-
four patients stratified in blocks of six were expected to be en-
rolled from each center.” and ’ “Patients were allocated to one
of the three treatment groups (placebo, SAMe, or naproxen) ac-
cording to randomisation schedules previously established for
each center.”’
Allocation concealment? Unclear No information provided
Blinding of patients? Yes The trial was described as a double-blind study randomising
patients to indistinguishable interventions
Blinding of physicians? Unclear No information provided
Blinding of outcome assessors? Unclear No information provided
Interventions reported as indistinguish-
able?
Yes Quote: “The tablets of active drugs and placebo were indistin-
guishable as to color, shape, taste, and smell”
Double-dummy technique used? No -
Intention-to-treat analysis performed?
Pain
No 235 out of 248 (95%) in SAMe group, 223 out of 241 (92%)
in placebo group analysed
Patients who withdrew because of side effects and those who
were lost to follow up were excluded. Patients who withdrew
because of ineffective therapy were included in the analysis.
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Caruso 1987 (Continued)
Intention-to-treat analysis performed?
Function
No See above
Funding by commercial organisation
avoided?
No S-adenosylmethionine tablets were provided by BioResearch
König 1990
Methods Randomised controlled trial
2-arm parallel group design
Trial duration: 12 weeks
Power calculation: not reported
Funding by non-profit organisation: no information provided
Participants 10 patients were randomised
10 patients with osteoarthritis were reported at baseline
Affected joints: 10 knees
Number of females: not reported
Average age: not reported, range 26 to 63 years
Average disease duration: not reported
Radiographic severity of OA: clinical evidence of osteoarthritis but without typical ra-
diographic signs (subchondral sclerosis, osteophytes, subchondral cysts)
Interventions Experimental intervention: S-Adenosylmethionine (Gumbaral), 400 mg 3 times daily
for 3 weeks, thereafter 400 mg twice daily
Control intervention: placebo, 3 times daily for 3 weeks, thereafter twice daily
Treatment duration: 12 weeks
Unclear whether analgesics were allowed and the intake was assessed
Outcomes Reported pain outcome: pain on walking after 12 weeks, described as “walking without
complaints”
Extracted function outcome: composite disability scores other than WOMAC after 12
weeks, described as “7 items covering pain at night, morning stiffness, walking limita-
tions, activity in daily life, local pain, crepitation, flexion/extension”
No primary outcome reported
Notes Not enough data provided for pain outcome to calculate standardised mean differences
and the study was therefore not included in the pain analyses. Contact with Dr Wacker
was established, but he was unable to provide additional data. Dr Wacker provided us
the current e-mail address of Dr. König, but latter did not reply to any of our e-mails.
Risk of bias
Item Authors’ judgement Description
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König 1990 (Continued)
Adequate sequence generation? Unclear No information provided
Allocation concealment? Unclear No information provided
Blinding of patients? Unclear Although the trial was described as double-blind, blinding of
patients was not specifically mentioned, nor were placebo tablets
described as indistinguishable from active tablets
Blinding of physicians? Unclear No information provided
Blinding of outcome assessors? Unclear No information provided
Interventions reported as indistinguish-
able?
No -
Double-dummy technique used? No -
Intention-to-treat analysis performed?
Pain
No 5 out of 6 (83%) in SAMe group, 4 out of 4 (100%) in placebo
group analysed
Intention-to-treat analysis performed?
Function
No 5 out of 6 (83%) in SAMe group, 4 out of 4 (100%) in placebo
group analysed
Funding by commercial organisation
avoided?
Unclear No information provided
Montrone 1985
Methods Quasi-randomised trial
2-arm parallel group design
Trial duration: 3 weeks
Power calculation: not reported
Funding by non-profit organisation: no information provided
Participants 76 patients were randomised
76 patients with osteoarthritis were reported at baseline
Affected joints: 51 knees and 25 hips
Number of females: not reported
Average age: not reported, range 40 to 75 years
Average disease duration: not reported, but more than 1 year
Radiographic severity of OA: functional classes II and Ill according to the classification
of the American Rheumatism Association (ARA)
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Montrone 1985 (Continued)
Interventions Experimental intervention: S-Adenosylmethionine, 400 mg 3 times daily
Control intervention: placebo, 3 times daily
Treatment duration: 3 weeks
Unclear whether analgesics were allowed and the intake was assessed
Outcomes Reported pain outcome: pain on activities other than walking after 3 weeks, described
as “weight bearing pain”
Reported function outcome: composite disability scores other than WOMAC after 3
weeks, described as “pooled results from items: going upstairs and downstairs, standing
up from chair, getting out of bed”
No primary outcome reported
Notes Not enough data provided for pain and function outcomes to calculate standardised
mean differences and the study was therefore not included in the main analyses. We were
unable to retrieve contact details of the first, second and last author of the report. Sarzi-
Puttini was contacted by e-mail, but he did not reply. Further attempts by phone were
unsuccessful.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear This double blind trial was published in 1985 as a short letter to
the editor of Clinical Rheumatology. We assumed that treatment
allocationwas at random, although the letter does not specifically
mention the use of randomisation.
Allocation concealment? Unclear See above
Blinding of patients? Yes The trial was described as double-blind study randomising pa-
tients to indistinguishable interventions
Blinding of physicians? Yes Physicians were blinded, as can be derived from the following
quote “At the end of the treatment in double-blind conditions,
both the physician and patients expressed a judgment on the
overall effectiveness of the therapy”.
Blinding of outcome assessors? Yes Unclear whether extracted pain and function outcomes were
recorded by patients or by physicians. However, physicians were
blinded, as can be derived from the following quote “At the end
of the treatment in double-blind conditions, both the physician
and patients expressed a judgment on the overall effectiveness
of the therapy”.
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Montrone 1985 (Continued)
Interventions reported as indistinguish-
able?
Yes Quote: “SAMe and Placebo were issued in 200 mg tablets iden-
tical in colour, shape and taste.”
Double-dummy technique used? No -
Intention-to-treat analysis performed?
Pain
No 32 out of 39 (82%) in SAMe group, 34 out of 37 (92%) in
placebo group analysed
Intention-to-treat analysis performed?
Function
No 32 out of 39 (82%) in SAMe group, 34 out of 37 (92%) in
placebo group analysed
Funding by commercial organisation
avoided?
Unclear No information provided
HAQ = health assessment questionnaire
OA = osteoarthritis
SAMe = S-Adenosylmethionine
Characteristics of excluded studies [ordered by study ID]
Bottiglieri 2002 No randomised controlled trial (review)
Caroli 1980 Only active control intervention (aspirin). Additional description: RCT
Ceccato 1980 Only active control intervention (ibuprofen). Additional description: RCT
Conis 2003 Not a randomised controlled trial (review)
Cucinotta 1980 Only active control intervention (ibuprofen). Additional description: RCT
Fagan 2002 No randomised controlled trial (review)
Pellegrini 1980 Only active control intervention (celecoxib). Additional description: RCT
Polli 1975 Less than 50% of patients had osteoarthritis and it was unclear whether the study was a randomised controlled
trial
Schardt 2003 Not a randomised controlled trial (review)
Schoenhals 2005 Not a randomised controlled trial (review)
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D A T A A N D A N A L Y S E S
Comparison 1. S-Adenosylmethionine versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain 2 533 Std. Mean Difference (Random, 95% CI) -0.17 [-0.35, 0.01]
2 Function 3 542 Std. Mean Difference (Random, 95% CI) 0.02 [-0.68, 0.71]
3 Number of patients experiencing
any adverse event
4 623 Risk Ratio (IV, Random, 95% CI) 1.27 [0.94, 1.71]
4 Number of patients who
withdrew because of adverse
events
4 656 Risk Ratio (IV, Random, 95% CI) 0.94 [0.48, 1.86]
Analysis 1.1. Comparison 1 S-Adenosylmethionine versus placebo, Outcome 1 Pain.
Review: S-Adenosylmethionine for osteoarthritis of the knee or hip
Comparison: 1 S-Adenosylmethionine versus placebo
Outcome: 1 Pain
Study or subgroup Experimental Control Std. Mean Difference (SE) Std. Mean Difference Weight Std. Mean Difference
N N IV,Random,95% CI IV,Random,95% CI
Bradley 1994 37 38 -0.216 (0.482) 3.7 % -0.22 [ -1.16, 0.73 ]
Caruso 1987 235 223 -0.166 (0.094) 96.3 % -0.17 [ -0.35, 0.02 ]
Total (95% CI) 100.0 % -0.17 [ -0.35, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.069)
-2 -1 0 1 2
Favours experimental Favours control
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Analysis 1.2. Comparison 1 S-Adenosylmethionine versus placebo, Outcome 2 Function.
Review: S-Adenosylmethionine for osteoarthritis of the knee or hip
Comparison: 1 S-Adenosylmethionine versus placebo
Outcome: 2 Function
Study or subgroup Experimental Control Std. Mean Difference (SE) Std. Mean Difference Weight Std. Mean Difference
N N IV,Random,95% CI IV,Random,95% CI
Knig 1990 5 4 1.404 (0.769) 15.6 % 1.40 [ -0.10, 2.91 ]
Bradley 1994 37 38 -0.441 (0.492) 27.6 % -0.44 [ -1.41, 0.52 ]
Caruso 1987 235 223 -0.137 (0.094) 56.7 % -0.14 [ -0.32, 0.05 ]
Total (95% CI) 100.0 % 0.02 [ -0.68, 0.71 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 4.38, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 0.06 (P = 0.96)
-2 -1 0 1 2
Favours experimental Favours control
Analysis 1.3. Comparison 1 S-Adenosylmethionine versus placebo, Outcome 3 Number of patients
experiencing any adverse event.
Review: S-Adenosylmethionine for osteoarthritis of the knee or hip
Comparison: 1 S-Adenosylmethionine versus placebo
Outcome: 3 Number of patients experiencing any adverse event
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Knig 1990 2/6 0/4 1.1 % 3.57 [ 0.21, 59.39 ]
Montrone 1985 3/39 6/37 5.2 % 0.47 [ 0.13, 1.76 ]
Bradley 1994 17/41 11/40 23.0 % 1.51 [ 0.81, 2.81 ]
Caruso 1987 57/236 42/220 70.8 % 1.27 [ 0.89, 1.80 ]
Total (95% CI) 322 301 100.0 % 1.27 [ 0.94, 1.71 ]
Total events: 79 (Experimental), 59 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.98, df = 3 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
0.1 0.2 0.5 1 2 5 10
Favours experimental Favours control
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Analysis 1.4. Comparison 1 S-Adenosylmethionine versus placebo, Outcome 4 Number of patients who
withdrew because of adverse events.
Review: S-Adenosylmethionine for osteoarthritis of the knee or hip
Comparison: 1 S-Adenosylmethionine versus placebo
Outcome: 4 Number of patients who withdrew because of adverse events
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Knig 1990 1/6 0/4 5.2 % 2.14 [ 0.11, 42.52 ]
Bradley 1994 2/41 1/40 8.3 % 1.95 [ 0.18, 20.68 ]
Montrone 1985 3/39 2/37 15.4 % 1.42 [ 0.25, 8.04 ]
Caruso 1987 10/248 13/241 71.2 % 0.75 [ 0.33, 1.67 ]
Total (95% CI) 334 322 100.0 % 0.94 [ 0.48, 1.86 ]
Total events: 16 (Experimental), 16 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.19, df = 3 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
0.1 0.2 0.5 1 2 5 10
Favours experimental Favours control
A P P E N D I C E S
Appendix 1. MEDLINE, EMBASE and CINAHL search strategy
OVID MEDLINE OVID EMBASE CINAHL through EBSCOhost
Search terms for design
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized controlled trial.sh.
4. random allocation.sh.
5. double blind method.sh.
6. single blind method.sh.
7. clinical trial.pt.
8. exp clinical trial/
9. (clin$ adj25 trial$).ti,ab.
10. ((singl$ or doubl$ or trebl$ or
tripl$) adj25 (blind$ or
mask$)).ti,ab.
Search terms for design
1. randomized controlled trial.sh.
2. randomization.sh.
3. double blind procedure.sh.
4. single blind procedure.sh.
5. exp clinical trials/
6. (clin$ adj25 trial$).ti,ab.
7. ((singl$ or doubl$ or trebl$ or
tripl$) adj25
(blind$ or mask$)).ti,ab.
8. placebo.sh.
9. placebo$.ti,ab.
10. random$.ti,ab.
Search terms for design
1. (MH “Clinical Trials+”)
2. (MH “Random Assignment”)
3. (MH “Double-Blind Studies”) or
(MH “Single-Blind Studies”)
4. TX (clin$ n25 trial$)
5. TX (sing$ n25 blind$)
6. TX (sing$ n25 mask$)
7. TX (doubl$ n25 blind$)
8. TX (doubl$ n25 mask$)
9. TX (trebl$ n25 blind$)
10. TX (trebl$ n25 mask$)
11. TX (tripl$ n25 blind$)
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(Continued)
11. placebos.sh.
12. placebo$.ti,ab.
13. random$.ti,ab.
14. research design.sh.
15. comparative study.sh.
16. exp evaluation studies/
17. follow up studies.sh.
18. prospective studies.sh.
19. (control$ or prospectiv$ or
volunteer$).ti,ab.
11. methodology.sh.
12. comparative study.sh.
13. exp evaluation studies/
14. follow up.sh.
15. prospective study.sh.
16. (control$ or prospectiv$ or
volunteer$).ti,ab.
12. TX (tripl$ n25 mask$)
13. (MH “Placebos”)
14. TX placebo$
15. TX random$
16. (MH “Study Design+”)
17. (MH “Comparative Studies”)
18. (MH “Evaluation Research”)
19. (MH “Prospective Studies+”)
20. TX (control$ or prospectiv$ or
volunteer$)
21. S1 or S2 or (…….) or S20
Search terms for Osteoarthritis
20. exp osteoarthritis/
21. osteoarthriti$.ti,ab,sh.
22. osteoarthro$.ti,ab,sh.
23. gonarthriti$.ti,ab,sh.
24. gonarthro$.ti,ab,sh.
25. coxarthriti$.ti,ab,sh.
26. coxarthro$.ti,ab,sh.
27. arthros$.ti,ab.
28. arthrot$.ti,ab.
29. ((knee$ or hip$ or joint$) adj3 (pain$
or
ach$ or discomfort$)).ti,ab.
30. ((knee$ or hip$ or joint$) adj3
stiff$).ti,ab.
Search terms for Osteoarthritis
17. exp osteoarthritis/
18. osteoarthriti$.ti,ab,sh.
19. osteoarthro$.ti,ab,sh.
20. gonarthriti$.ti,ab,sh.
21. gonarthro$.ti,ab,sh.
22. coxarthriti$.ti,ab,sh.
23. coxarthro$.ti,ab,sh.
24. arthros$.ti,ab.
25. arthrot$.ti,ab.
26. ((knee$ or hip$ or joint$) adj3
(pain$ or ach$ or
discomfort$)).ti,ab.
27. ((knee$ or hip$ or joint$) adj3
stiff$).ti,ab.
Search terms for Osteoarthritis
22. osteoarthriti$
23. (MH “Osteoarthritis”)
24. TX osteoarthro$
25. TX gonarthriti$
26. TX gonarthro$
27. TX coxarthriti$
28. TX coxarthro$
29. TX arthros$
30. TX arthrot$
31. TX knee$ n3 pain$
32. TX hip$ n3 pain$
33. TX joint$ n3 pain$
34. TX knee$ n3 ach$
35. TX hip$ n3 ach$
36. TX joint$ n3 ach$
37. TX knee$ n3 discomfort$
38. TX hip$ n3 discomfort$
39. TX joint$ n3 discomfort$
40. TX knee$ n3 stiff$
41. TX hip$ n3 stiff$
42. TX joint$ n3 stiff$
43. S22 or S23 or S24….or S42
Search terms for S-Adenosylmethionine
31. exp S-Adenosylmethionine/
32. Sadenosylmethionine.tw.
33. S-adenosylmethionine.tw.
34. Adenosyl-l-met*ionine.tw.
35. ademet*ionin*.tw.
36. methionine.tw
37. metionine.tw
38. heptral.tw.
39. Adomet.tw.
Search terms for S-Adenosylmethionine
28. exp S-Adenosylmethionine/
29. Sadenosylmethionine.tw.
30. S-adenosylmethionine.tw.
31. Adenosyl-l-met*ionine.tw.
32. ademet*ionin*.tw.
33. methionine.tw
34. metionine.tw
35. ademetionin*.tw.
36. heptral.tw.
Search terms for S-Adenosylmethionine
44. (MH “S-Adenosylmethionine”)
45. TX Sadenosylmethionine
46. TX S-adenosylmethionine
47. TX Adenosyl-l-met*ionine
48. TX ademet*ionin*
49. TX methionine
50. TX metionine
51. TX heptral
52. TX Adomet
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(Continued)
40. Gumbaral.tw.
41. SAM-e.tw.
42. Transmetil.tw.
43. SD4.tw.
44. Samyr.tw.
37. Adomet.tw.
38. Gumbaral.tw.
39. SAM-e.tw.
40. Transmetil.tw.
41. SD4.tw.
42. Samyr.tw.
53. TX Gumbaral
54. TX SAM-e
55. TX Transmetil
56. TX SD4
57. TX Samyr
58. S44 or S45 or …. S57
Combining terms
45. or/1-19
46. or/20-30
47. or/31-44
48. and/45-47
49. animal/
50. animal/ and human/
51. 49 not 50
52. 48 not 51
Combining terms
42. or/1-16
43. or/17-27
44. or/28-41
45. and/42-44
46. animal/
47. animal/ and human/
48. 46 not 47
49. 45 not 48
Combining terms
S21 and S43 and S59
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Appendix 2. CENTRAL search strategy
CENTRAL
Search terms for Osteoarthritis
#1. (osteoarthritis* OR osteoarthro* OR gonarthriti* OR gonarthro*
OR coxarthriti* OR coxarthro* OR arthros* OR arthrot* OR
((knee* OR hip* OR joint*) near/3 (pain* OR ach* OR discomfort*))
OR ((knee* OR hip* OR joint*) near/3 stiff*)) in Clinical Trials
#2. MeSH descriptor Osteoarthritis explode all trees
Search terms for S-Adenosylmethionine
#3. MeSH descriptor S-Adenosylmethionine explode all trees
#4. Sadenosylmethionine in Clinical Trials
#5. S-adenosylmethionine in Clinical Trials
#6. Adenosyl-l-met*ionine in Clinical Trials
#7. ademet*ionin* in Clinical Trials
#8. methionine.tw in Clinical Trials
#9. metionine.tw in Clinical Trials
#10. heptral in Clinical Trials
#11. Adomet in Clinical Trials
#12. Gumbaral in Clinical Trials
#13. SAM-e in Clinical Trials
#14. Transmetil in Clinical Trials
#15. SD4 in Clinical Trials
#16. Samyr in Clinical Trials
Combining terms
#17. (#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR
#11 OR #12 OR #13 OR #14 OR #15 OR #16)
#18. (#1 OR #2)
#19. (#17 AND #18) in Clinical Trials
WH A T ’ S N E W
Last assessed as up-to-date: 4 August 2008.
1 May 2008 Amended CMSG ID C178-R
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H I S T O R Y
Protocol first published: Issue 3, 2008
Review first published: Issue 4, 2009
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Analysis and interpretation of data: Rutjes, Nüesch, Reichenbach, Jüni
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Before embarking on this review, we generated a standard protocol for this, and all other Cochrane Reviews performed by our group.
The protocol was approved by the Editorial Board of the Cochrane Musculoskeletal Review Group (CMSG). Due to the low number
of trials included, we had to deviate from the original protocol in some aspects. We could not explore the association between trial
size and treatment effects with funnel plots and could not perform stratified analyses, which were planned to evaluate if treatment
effects on pain and function were affected by type of control (placebo or sham intervention versus no intervention), concealment of
allocation (adequate versus inadequate or unclear), blinding of patients (adequate versus inadequate or unclear), analysis in accordance
with the intention-to-treat principle (yes versus no or unclear), trial size, funding, and differences in the use of co-interventions in the
trial groups. In addition, we anticipated including dosage of intervention as continuous variables at trial level. Finally, visual inspection
revealed a potential outlier in the heterogeneous meta-analysis of function and we performed a sensitivity analysis excluding this outlier
as required by one of the peer reviewers.
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